Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study

Table 5 Percentage change from baseline in standardized seizure frequency, and responder rate by seizure type during the monotherapy period (EFF population)

	n		Median change from baseline (%)		Responder rate (%) ^*
	ESL 1200 mg	ESL 1600 mg	ESL 1200 mg	ESL 1600 mg	ESL 1200 mg	ESL 1600 mg
Simple partial without motor	2	7	22.4	−100.0	0	85.7
Simple partial with motor	17	34	−38.5	−52.0	41.2	52.9
Complex partial	30	53	−70.9	−49.8	66.7	49.1
Partial evolving to secondary generalized	16	33	−51.3	−79.7	50.0	72.7

^*Patients with ≥50% reduction; calculated as percentage of patients in ESL dose group.
EFF = efficacy; ESL = eslicarbazepine acetate.

ISSN: 1471-2377